646 related articles for article (PubMed ID: 19658448)
1. Intravenous immunoglobulin-induced, non-eczematous, vesiculobullous eruptions in Stevens-Johnson syndrome.
Lin WL; Lin WC; Chang YC; Yang LC; Hung SI; Hong HS; Chung WH
Am J Clin Dermatol; 2009; 10(5):339-42. PubMed ID: 19658448
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
Yang Y; Xu J; Li F; Zhu X
Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
[TBL] [Abstract][Full Text] [Related]
3. Vesicular eczema after intravenous immunoglobulin therapy for treatment of Stevens-Johnson syndrome.
Young PK; Ruggeri SY; Galbraith S; Drolet BA
Arch Dermatol; 2006 Feb; 142(2):247-8. PubMed ID: 16490861
[No Abstract] [Full Text] [Related]
4. Early diagnosis is key in vancomycin-induced linear IgA bullous dermatosis and Stevens-Johnson syndrome.
Jones DH; Todd M; Craig TJ
J Am Osteopath Assoc; 2004 Apr; 104(4):157-63. PubMed ID: 15127983
[TBL] [Abstract][Full Text] [Related]
5. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature.
Vecchietti G; Kerl K; Prins C; Kaya G; Saurat JH; French LE
Arch Dermatol; 2006 Feb; 142(2):213-7. PubMed ID: 16490849
[TBL] [Abstract][Full Text] [Related]
6. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome.
Harr T; French LE
Med Clin North Am; 2010 Jul; 94(4):727-42, x. PubMed ID: 20609860
[TBL] [Abstract][Full Text] [Related]
7. Stevens-Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options.
Teo L; Tay YK; Liu TT; Kwok C
Singapore Med J; 2009 Jan; 50(1):29-33. PubMed ID: 19224081
[TBL] [Abstract][Full Text] [Related]
8. [Use of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis and Stevens-Johnson/toxic epidermal necrolysis overlap syndrome. Review of 15 cases].
Molgó M; Carreño N; Hoyos-Bachiloglu R; Andresen M; González S
Rev Med Chil; 2009 Mar; 137(3):383-9. PubMed ID: 19621180
[TBL] [Abstract][Full Text] [Related]
9. IVIG for the treatment of toxic epidermal necrolysis.
Mittmann N; Chan BC; Knowles S; Shear NH
Skin Therapy Lett; 2007 Feb; 12(1):7-9. PubMed ID: 17361314
[TBL] [Abstract][Full Text] [Related]
10. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine.
Kirchhof MG; Miliszewski MA; Sikora S; Papp A; Dutz JP
J Am Acad Dermatol; 2014 Nov; 71(5):941-7. PubMed ID: 25087214
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immunoglobulin therapy for Stevens-Johnson syndrome.
Brett AS; Philips D; Lynn AW
South Med J; 2001 Mar; 94(3):342-3. PubMed ID: 11284525
[TBL] [Abstract][Full Text] [Related]
12. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis.
Stella M; Clemente A; Bollero D; Risso D; Dalmasso P
Burns; 2007 Jun; 33(4):452-9. PubMed ID: 17475410
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Aihara M; Kano Y; Fujita H; Kambara T; Matsukura S; Katayama I; Azukizawa H; Miyachi Y; Endo Y; Asada H; Miyagawa F; Morita E; Kaneko S; Abe R; Ochiai T; Sueki H; Watanabe H; Nagao K; Aoyama Y; Sayama K; Hashimoto K; Shiohara T;
J Dermatol; 2015 Aug; 42(8):768-77. PubMed ID: 25982480
[TBL] [Abstract][Full Text] [Related]
14. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding.
French LE; Trent JT; Kerdel FA
Int Immunopharmacol; 2006 Apr; 6(4):543-9. PubMed ID: 16504917
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome.
Morici MV; Galen WK; Shetty AK; Lebouef RP; Gouri TP; Cowan GS; Gedalia A
J Rheumatol; 2000 Oct; 27(10):2494-7. PubMed ID: 11036849
[TBL] [Abstract][Full Text] [Related]
16. [Is intravenous immunoglobulin effective in toxic epidermal necrolysis and Stevens-Johnson syndrome?].
Navajas L; Rada G
Medwave; 2014 Oct; 14(9):e6024. PubMed ID: 25340656
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulins for the management of Stevens-Johnson syndrome with minimal skin manifestations.
Zipitis CS; Thalange N
Eur J Pediatr; 2007 Jun; 166(6):585-8. PubMed ID: 17008995
[TBL] [Abstract][Full Text] [Related]
18. Early treatment with nonsucrose intravenous immunoglobulin in a burn unit reduces toxic epidermal necrolysis mortality.
Aires DJ; Fraga G; Korentager R; Richie CP; Aggarwal S; Wick J; Liu DY
J Drugs Dermatol; 2013 Jun; 12(6):679-84. PubMed ID: 23839186
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin in the treatment of childhood Stevens Johnson syndrome.
Britton P; Deng L
J Paediatr Child Health; 2011 Jun; 47(6):392-5. PubMed ID: 21649751
[No Abstract] [Full Text] [Related]
20. The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre.
Lee HY; Lim YL; Thirumoorthy T; Pang SM
Br J Dermatol; 2013 Dec; 169(6):1304-9. PubMed ID: 24007192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
